Operating Data

Plus Therapeutics Inc

Plus Therapeutics Inc (PSTV)

$2.54
0.05 (+2.01%)
Year
A/P
2013
Actual
2014
Actual
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
Revenue 12.207.6011.6611.386.416.657.006.756.516.286.055.84
Revenue (%)
EBITDA -21.15-32.22-14.27-18.27-18.49-8.71-8.14-13.65-13.16-12.70-12.24-11.81
EBITDA (%)
EBIT -22.78-33.00-15.37-19.45-20.64-10.71-9.03-14.81-14.28-13.77-13.28-12.81
EBIT (%)
Depreciation 1.630.781.091.182.152.000.901.161.111.071.041.00
Depreciation (%)




EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT)
EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income)
EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization
EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company
(1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments),
(2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill)
(3*) collections of assets (by ignoring depreciation of assets)
(4*) different takeover histories (by ignoring amortization often stemming from goodwill)